Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy

► Substituting N-HDL-C by LDL increases the number of patients to be treated. ► 57% of hypertriglyceridemic patients with LDL on target have high N-HDL-C. ► Using N-HDL-C as treatment driver will increase cardiovascular prevention cost.